EGFR-activating mutations occur in about 10–15% of Caucasian and up to 50% of Asian NSCLC patients [5,6], while ALK and ROS1 rearrangements are detected in 3–7% [7] and 2% of cases, respectively [8,9]. Here, EGFR is linked to non-small cell lung carcinoma.